EQT

Vico Therapeutics B.V., founded in 2019 and based in Leiden, the Netherlands, specializes in developing RNA modulating therapies aimed at treating rare neurological disorders. The company's primary focus is on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome. By discovering and delivering innovative therapies, Vico Therapeutics aims to address the unmet medical needs of patients suffering from these severe central nervous system disorders, thereby enhancing treatment options available to medical professionals.

Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).

Vico Therapeutics B.V., founded in 2019 and based in Leiden, the Netherlands, specializes in developing RNA modulating therapies aimed at treating rare neurological disorders. The company's primary focus is on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome. By discovering and delivering innovative therapies, Vico Therapeutics aims to address the unmet medical needs of patients suffering from these severe central nervous system disorders, thereby enhancing treatment options available to medical professionals.

Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels, utilizing a proprietary polymer-based technology called RestoreX. This technology enables the patient's natural healing system to develop tissue that permeates the heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis' restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. The company has secured significant funding from investors such as EQT Life Sciences, Kurma Partners, and the European Investment Bank, totaling over €30 million.

Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels, utilizing a proprietary polymer-based technology called RestoreX. This technology enables the patient's natural healing system to develop tissue that permeates the heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis' restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. The company has secured significant funding from investors such as EQT Life Sciences, Kurma Partners, and the European Investment Bank, totaling over €30 million.

Storytel is a leading provider of audiobook and e-book streaming services, offering unlimited access to a diverse range of titles across more than 20 markets. Founded in 2005 and headquartered in Sweden, the company operates under the Storytel and Mofibo brands, providing users with the ability to explore a wide array of genres, including detective stories, novels, and biographies, in multiple languages such as Swedish, English, Arabic, Danish, and Finnish. Storytel also has a significant publishing division that includes several established publishing houses, such as Norstedts, Massolit, and B. Wahlstrom, focusing on both adult and children's literature. The company has expanded its services internationally, with operations in countries like Denmark, Norway, the Netherlands, and the USA, positioning itself as a prominent player in the subscription-based audiobook and e-book market.

ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

Storytel is a leading provider of audiobook and e-book streaming services, offering unlimited access to a diverse range of titles across more than 20 markets. Founded in 2005 and headquartered in Sweden, the company operates under the Storytel and Mofibo brands, providing users with the ability to explore a wide array of genres, including detective stories, novels, and biographies, in multiple languages such as Swedish, English, Arabic, Danish, and Finnish. Storytel also has a significant publishing division that includes several established publishing houses, such as Norstedts, Massolit, and B. Wahlstrom, focusing on both adult and children's literature. The company has expanded its services internationally, with operations in countries like Denmark, Norway, the Netherlands, and the USA, positioning itself as a prominent player in the subscription-based audiobook and e-book market.

Mollie is a payments platform based in Amsterdam, founded in 2004, that simplifies the integration of payment solutions for online businesses. Serving over 50,000 clients, the company supports a variety of local payment methods, including Mastercard, VISA, PayPal, and iDEAL, among others. Mollie's technology-driven approach allows merchants to easily implement payment systems through a simple yet powerful API, facilitating one-click payments, fraud monitoring, and real-time accounting. By streamlining the payment process, Mollie enables businesses to efficiently manage their finances and enhance revenue generation while minimizing operational complexities.

Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).

Vico Therapeutics B.V., founded in 2019 and based in Leiden, the Netherlands, specializes in developing RNA modulating therapies aimed at treating rare neurological disorders. The company's primary focus is on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome. By discovering and delivering innovative therapies, Vico Therapeutics aims to address the unmet medical needs of patients suffering from these severe central nervous system disorders, thereby enhancing treatment options available to medical professionals.

ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

Cybin is a biopharmaceutical company dedicated to advancing research and development in psychedelic and medicinal mushrooms. It focuses on creating safe and effective therapeutics for mental health issues, with an emphasis on psilocybin-based products. The company is actively launching these products in jurisdictions where they are permitted and is engaged in clinical studies across North America and other regions. Through strategic partnerships with academic and institutional entities, Cybin seeks to develop novel compounds and delivery mechanisms, aiming to provide innovative treatments for various psychiatric and neurological conditions.

Kiadis Pharma N.V. is a clinical-stage biopharmaceutical company based in Amsterdam, the Netherlands, specializing in the development of cell-based immunotherapy products for blood cancers and inherited blood disorders. The company is currently advancing its product pipeline, which includes K-NK002, an adjunctive immunotherapeutic in Phase II trials for blood cancer patients undergoing haploidentical hematopoietic stem cell transplants, and K-NK003, which is in Phase I/II trials for patients with acute myeloid leukemia who are relapsed or refractory. Additionally, Kiadis Pharma is developing K-NK00X, a preclinical NK-cell therapy candidate aimed at treating various solid tumors. The company is engaged in collaborative efforts with multiple institutions to explore innovative treatments, including a combination of a monoclonal antibody and natural killer cells for COVID-19. Established in 1997, Kiadis Pharma addresses critical unmet medical needs in oncology through its innovative therapeutic approaches.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

Veritas Petroleum Services is a global provider of testing, inspection, and advisory services, operating five laboratories strategically located in the Netherlands, Singapore, Houston, Fujairah, and Manchester. The company specializes in fuel quality testing, bunker quantity surveys, oil condition monitoring, and transformer oil testing, among other services. By offering these solutions, Veritas Petroleum Services assists clients in the marine, power, and renewable sectors to optimize their operational performance. The company focuses on helping its customers improve fuel management, reduce fuel costs, enhance operational efficiency, and comply with environmental regulations.

Caiway is a telecommunications infrastructure company based in the Netherlands, specializing in broadband services for over 350,000 households and businesses. The company has expanded its fiber network into remote areas, enhancing connectivity for municipalities and homes. As a regional internet service provider, Caiway offers a variety of services, including broadband, television, and telephony, delivered through its cable and fiber infrastructure. Major regions within Caiway's operational footprint include Westland, Schiedam, and Almelo, where it aims to provide reliable networking and high-quality service to its customers.

Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels, utilizing a proprietary polymer-based technology called RestoreX. This technology enables the patient's natural healing system to develop tissue that permeates the heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis' restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. The company has secured significant funding from investors such as EQT Life Sciences, Kurma Partners, and the European Investment Bank, totaling over €30 million.

DentConnect is a fast-growing platform of dental clinics, with activities in the Netherlands, Belgium, Denmark, Germany and Italy. DentConnect is headquartered in the Netherlands and serves over one million patients through its pan-European network of over 220 clinics. DentConnect acts as a multi-functional service organization for these clinics, allowing the dentists to fully focus on providing patients with the best possible care. DentConnect Shared Service Center supports and facilitates dentists with HR, Finance and administration, quality and care management, procurement, marketing and communication and general management.

TransIP Group B.V., established in 2003 and headquartered in Leiden, Netherlands, specializes in providing web hosting and related services. It caters primarily to tech-savvy customers and IT professionals, offering a range of products including virtual private servers, domain name registration, and web hosting. The company's notable services comprise BladeVPS PureSSD Pro, a self-managed tool with web control panels and operating systems, STACK for online file storage, syncing, and sharing, and SSL certificates for website encryption. Additionally, TransIP provides services like forwarding, big storage, and private network solutions. As of 2019, TransIP operates as a subsidiary of Combell nv.

Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).

ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels, utilizing a proprietary polymer-based technology called RestoreX. This technology enables the patient's natural healing system to develop tissue that permeates the heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis' restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. The company has secured significant funding from investors such as EQT Life Sciences, Kurma Partners, and the European Investment Bank, totaling over €30 million.

Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels, utilizing a proprietary polymer-based technology called RestoreX. This technology enables the patient's natural healing system to develop tissue that permeates the heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis' restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. The company has secured significant funding from investors such as EQT Life Sciences, Kurma Partners, and the European Investment Bank, totaling over €30 million.

Kiadis Pharma N.V. is a clinical-stage biopharmaceutical company based in Amsterdam, the Netherlands, specializing in the development of cell-based immunotherapy products for blood cancers and inherited blood disorders. The company is currently advancing its product pipeline, which includes K-NK002, an adjunctive immunotherapeutic in Phase II trials for blood cancer patients undergoing haploidentical hematopoietic stem cell transplants, and K-NK003, which is in Phase I/II trials for patients with acute myeloid leukemia who are relapsed or refractory. Additionally, Kiadis Pharma is developing K-NK00X, a preclinical NK-cell therapy candidate aimed at treating various solid tumors. The company is engaged in collaborative efforts with multiple institutions to explore innovative treatments, including a combination of a monoclonal antibody and natural killer cells for COVID-19. Established in 1997, Kiadis Pharma addresses critical unmet medical needs in oncology through its innovative therapeutic approaches.

Atos Medical was founded in 1986 and today has a vast international network with subsidiaries in the USA, UK, Germany, Spain, Netherlands, Belgium, Sweden and Switzerland and also exclusive distributors serving about 60 countries. The head office is situated in Sweden, where a state-of-the-art clean room and laboratory make it possible to perform all tests required for successful R&D.

Sapiens Steering Brain Stimulation GmbH is a medical device company focused on advancing deep brain stimulation (DBS) therapy. Founded in 2011 as a spin-out of Royal Philips Electronics, the company aims to enhance patient comfort and therapeutic outcomes with its innovative, high-resolution, and MRI-compatible DBS system. Sapiens specializes in developing a comprehensive DBS solution that includes navigation and steering software, as well as implants specifically designed for patients with Parkinson's disease. With offices in Eindhoven, the Netherlands, and Munich, Germany, Sapiens leverages patented technologies to deliver effective and precise treatment options for individuals suffering from this neurological condition.

Argenx is a global immunology company based in the Netherlands, dedicated to enhancing the lives of individuals affected by severe autoimmune diseases and cancer. The company specializes in antibody engineering technology to develop treatments for rare autoimmune conditions. Its lead product, Vyvgart (efgartigimod), received initial approval in the United States in December 2021 for the treatment of generalized myasthenia gravis, followed by subsequent approvals in Europe and Japan in 2022. Through its innovative approaches, Argenx aims to address significant unmet medical needs in the field of immunology.

BMEYE B.V., based in Amsterdam, Netherlands, is a company focused on non-invasive cardiovascular monitoring through the research and development of advanced medical technologies. The company provides a range of products designed to measure blood pressure and cardiac output, including the Finapres and Portapres, which are continuous finger blood pressure monitors, and the Finometer, a stationary device for brachial pressure and hemodynamic assessments. BMEYE also offers BeatScope software for arterial pressure waveform analysis, Modelflow for aortic flow waveform computation, and devices like Cardiopres and Oxyflow for specialized research and clinical applications. Its Nexfin and ccNexfin products are approved for use in the U.S. and Europe, catering to cardiology, anesthesiology, and critical care environments. BMEYE distributes its innovative monitoring solutions through a network of partners, aiming to enhance cardiovascular care and research globally.

Kiadis Pharma N.V. is a clinical-stage biopharmaceutical company based in Amsterdam, the Netherlands, specializing in the development of cell-based immunotherapy products for blood cancers and inherited blood disorders. The company is currently advancing its product pipeline, which includes K-NK002, an adjunctive immunotherapeutic in Phase II trials for blood cancer patients undergoing haploidentical hematopoietic stem cell transplants, and K-NK003, which is in Phase I/II trials for patients with acute myeloid leukemia who are relapsed or refractory. Additionally, Kiadis Pharma is developing K-NK00X, a preclinical NK-cell therapy candidate aimed at treating various solid tumors. The company is engaged in collaborative efforts with multiple institutions to explore innovative treatments, including a combination of a monoclonal antibody and natural killer cells for COVID-19. Established in 1997, Kiadis Pharma addresses critical unmet medical needs in oncology through its innovative therapeutic approaches.

BMEYE B.V., based in Amsterdam, Netherlands, is a company focused on non-invasive cardiovascular monitoring through the research and development of advanced medical technologies. The company provides a range of products designed to measure blood pressure and cardiac output, including the Finapres and Portapres, which are continuous finger blood pressure monitors, and the Finometer, a stationary device for brachial pressure and hemodynamic assessments. BMEYE also offers BeatScope software for arterial pressure waveform analysis, Modelflow for aortic flow waveform computation, and devices like Cardiopres and Oxyflow for specialized research and clinical applications. Its Nexfin and ccNexfin products are approved for use in the U.S. and Europe, catering to cardiology, anesthesiology, and critical care environments. BMEYE distributes its innovative monitoring solutions through a network of partners, aiming to enhance cardiovascular care and research globally.

DNage is a life sciences company founded in 2004 as a spin off from the Department of Genetics of the Erasmus Medical Center Rotterdam. The Company was seed-funded through an equity investment of an international syndicate of venture capitalists including LSP (NL) and Inventages (CH).

Haanpaa is a logistics company specializing in the distribution of chemical products across Europe. Founded in 1949 by Jussi Haanpaa and headquartered in Vantaa, Finland, the company offers a range of services including storage, maintenance, transportation, and delivery in various European cities. Haanpaa also engages in sampling, monitoring, and packaging of chemical products, along with tank inspection and customer support services. The company produces specialty chemicals, pulps and papers, fuels, lubricants, animal feeds, and agricultural commodities. With branches in Finland, Sweden, Norway, Estonia, Russia, and the Netherlands, Haanpaa has established a strong presence in the logistics sector for liquid chemical products. Since July 2016, it has operated as a subsidiary of Groupe Samat SA.